TFS Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

TFS Capital’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,587	Closed	-$203K	–	507
2017 Q2	$203K	Buy	+10,587	New	+$169K	0.08%	448

Other funds holding BOLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's BOLD Position: Q3 2017 in Review

TFS Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2017, closing a stake of 10,587 shares — an estimated $203K sold.

TFS Capital first reported a position in BOLD in Q2 2017 and held it in 1 quarter. The position peaked at $203K in Q2 2017. 81 funds tracked by Wall St. Rank hold BOLD as of Q3 2017.

TFS Capital reported no remaining Audentes Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 10,587 Audentes Therapeutics, Inc shares in Q3 2017, an estimated $203K.
TFS Capital first reported a position in Audentes Therapeutics, Inc in Q2 2017 and held it in 1 quarter.
TFS Capital's Audentes Therapeutics, Inc position peaked at $203K in Q2 2017.
81 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.